Synapse - Weinberg Fellows

Results (339)

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

Journal Article

Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing

Research Letter

Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction

Journal Article

Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
Blood Advances (2025)

Fulltext@MSK | Save

More than myeloma: The trouble with “normal” plasma cells

Editorial

Firestone, R. S.; Maura, F.
Blood (2025)

Fulltext@MSK | Save

Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype

Journal Article

Galera, P.; Dilip, D.; Derkach, A.; Chan, A.; Zhang, Y.; Persaud, S.; Mishra, T.; Kramer, K.; Kathpalia, M.; Liu, Y.; more...
Blood (2025)

Fulltext@MSK | Save

α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia

Journal Article

Millman, S. E.; Chaves-Perez, A.; Janaki-Raman, S.; Ho, Y. J.; Morris, J. P. 4th; Narendra, V.; Chen, C. C.; Jackson, B. T.; Yashinskie, J. J.; Mezzadra, R.; more...
Blood (2025)

Fulltext@MSK | Save

Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from the PETAL consortium

Journal Article

Han, J. X.; Koh, M. J.; Boussi, L.; Sorial, M.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J.; more...
Blood Advances (2025)

Fulltext@MSK | Save

Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation

Journal Article

Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chhabra, S.; Chabowska, M.; Dogan, A.; Falchi, L.; Grieve, C.; more...
Blood (2025)

Fulltext@MSK | Save

A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)

Meeting Abstract

Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; more...
Blood (2024)

Fulltext@MSK | Save

Results from the Great Britain AML real world evidence (ARC) initiative - A centre-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia

Meeting Abstract

O'Nions, J.; Errico, G.; Floro, L.; Murthy, V.; Sweeney, C.; Kaur, H.; Mohite, U.; Ayto, R.; Alvares, C.; Goldberg, A. D.; more...
Blood (2024)

Fulltext@MSK | Save